Feed RARE
RA

Ultragenyx Pharmaceutical

RARE · NASDAQ

$14.50 +9.15% (+$1.21)
1M -44.74%
Market Cap $1.43B
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$16.56

14.2% upside

Current Price

$14.5

Undervalued Fair Value Overvalued

According to Bulios Fair Price, RARE is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
2/9
Valuation
75 /100
Cheap
P/S 1.99x
EV/FFO N/A
P/B N/A
Growth
100 /100
Growing
Rev. growth 22.81%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak
Net margin 81.79%
Op. margin 73.77%
FCF margin 68.27%
Quality
10 /100
Poor
ROA 46.39%
Asset turnover 0.57x
ROIC 53.83%
Debt
37 /100
Moderate
Int. coverage -6.65x
Current ratio 1.73x
Net debt/EBITDA N/A
Stability
68 /100
Stable
Rev. volatility 5.31%
EPS volatility 8.40%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about RARE
Online

About the company

Ultragenyx Pharmaceutical is a biotechnology company focused on developing innovative therapeutic options for rare genetic diseases. The company specializes in developing drugs that target specific genetic mutations or metabolic pathways that cause various rare diseases, including genetic disorders that affect metabolism, growth, and development. Ultragenyx focuses on conditions for which there are limited available treatment options and strives to improve the lives of patients with these diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Emil D. Kakkis

Employees

1,371

Headquarters

Novato

Upcoming events

03 NOV

Earnings

Upcoming earnings report

46d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.